44 Views

CRT 2026

Spotlight

Session:: Beyond the Guidelines | Aortic Valve: Bicuspid | Lifetime Management | Redo Versus Explant | Asymptomatic Aortic Stenosis [Non-CME]

What Does the Data Tell us on Asymptomatic AS | Does it Move the Needle for Guideline Endorsement?

Saturday, March 7, 2026

4:16 PM - 4:24 PM EST

Location: Spotlight Theater

Speaker(s)

Howard C. Herrmann, MD, FACC, MSCAI

John Bryfogle Professor Emeritus of Cardiovascular Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania, United States

Disclosure(s): Affluent Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Artedrone: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Caranx: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Mass Medical Society: Editorial Fees (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); MicroInterventional Devices: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing)

Disclosure(s):

Howard C. Herrmann, MD, FACC, MSCAI: Affluent Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Artedrone: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Caranx: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Mass Medical Society: Editorial Fees (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); MicroInterventional Devices: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing)